- Global Pharma News & Resources


Over the past 12 months, Ellab Group has acquired a quintet of European companies to consolidate its position as a leader in validation, calibration, and monitoring solutions for the pharmaceutical and biotech industries. Ellab has invested more than 23 million EUR in the five companies located in Ireland, Italy, the Netherlands, and Denmark the past year alone.

Kristoffer Lecker Johannessen, Head of Mergers & Acquisitions (M&A) at Ellab, explains that the acquisitions are part of a long-term strategy to offer a one-stop shop for world-class validation, calibration, and monitoring solutions.

He said: “We seek to acquire the best service providers in all our geographic markets. Our M&A strategy is key to our ambition for continued growth in our field service segment. This will enable us to expand our services to existing customers, while we can also extend our class-leading solutions to new customers.”

In the past three years, Ellab Group has bought 11 companies. In 2022 the Ellab family has been expanded with Causa, one of the leading Dutch providers of qualification and validation services specialized in disinfection and sterilization equipment in the pharmaceutical, healthcare and food industries; Italy-based Clover Life Science, which supports blue-chip companies within the biotech, pharmaceutical, medical equipment, food and cosmetics sectors; Autocal Ireland, specializing in all areas of thermal mapping and project management, delivering services to the pharmaceutical and healthcare industries in Ireland; and the Danish company Project Support which delivers validation and accredited calibration services to key customers in Denmark.

The latest acquisition is CalX Instrumentation Services Limited, a leading Irish provider of field calibration and complete calibration management, strengthening Ellab Ireland’s portfolio of validation, calibration and monitoring solutions in the country and increasing the workforce from 40 to 85 employees in total.

With the acquisitions, the number of employees in Ellab worldwide is now around 660, 270 of which are field service engineers and GMP consultants.

Kristoffer Lecker Johannessen emphasizes that Ellab's M&A strategy is not about buying people out, but is an invitation to successful companies to join the Ellab Group so that they can continue growth together. The new acquisitions can continue to develop the business under Ellab’s motto of "global expertise with local reach". This includes enabling local teams to operate independently so that they maintain their autonomy and local presence. The volume of acquisitions in 2022 is part of the vision to continuously strengthen and improve the local experience of customers when they do business with any Ellab company, anywhere in the world.

In addition to its headquarters in Hillerød, Denmark, Ellab now has sales and service offices in the USA, UK, Ireland, Germany, France, Switzerland, Austria, Italy, Spain, the Netherlands, the UAE and the Philippines – with a new office being established in Singapore.

Despite the challenges of a global pandemic and the war in Ukraine, Ellab Group's strategy is to invest in companies that can enhance the group's global reach - to deliver the best quality and services to a wider audience and together build confidence in consumer safety. The ambition for the group is to continue with double-digit organic and acquisition-related growth in the coming years.

In addition to its world-renowned validation, monitoring and calibration solutions and services, Ellab also provides leading GMP consulting and related products to life science and food manufacturing companies globally.

For more information visit

Editor Details

Related Links

Last Updated: 18-Oct-2022